PREDILIFE: directors' dealings · France · AMF

About PREDILIFE

PREDILIFE is a French company specializing in predictive medicine, listed on Euronext Growth Paris under ISIN code FR0010169920 and ticker ALPRE. Founded in 2004, the company was built around a clear mission: to make personalized prevention more accessible by combining artificial intelligence, Big Data and clinically validated medical methods. Its positioning sits at the intersection of healthcare, diagnostics and disease prevention, with a strong technology component. The company’s history is rooted in a long research and development cycle. After roughly 14 years of R&D, PREDILIFE obtained medical device certification and launched its first predictive health check-ups in France and internationally. Its flagship product, MammoRisk®, was developed to assess breast cancer risk using reference clinical databases and advanced statistical models. This product helped establish PREDILIFE as a pioneer in personalized prevention, particularly in oncology. Since 2021, the company has expanded its predictive portfolio to cover several other major conditions, including prostate cancer, melanoma, colorectal cancer, lung cancer and cardiovascular disease. This diversification strengthens the company’s value proposition: offering predictive tests that can identify significant health risks earlier, thereby improving prevention, screening and medical follow-up. PREDILIFE also markets predictive check-ups for companies, helping HR teams and occupational health departments structure prevention initiatives for employees. From a market standpoint, PREDILIFE operates in a specialized niche within digital health and medical prevention. Its model addresses a market that is still relatively early-stage and not fully standardized, but one that offers meaningful growth potential as employers, healthcare providers and institutions seek more targeted screening solutions. The company highlights partnerships with major international databases and with recognized healthcare institutions in France and Europe. Its geographic footprint remains primarily centered on France, while its offering is designed for broader international expansion. Notable features of PREDILIFE include its science-driven model, which combines medical research, algorithms and individualized prevention. The company also emphasizes the economic rationale of its predictive check-ups, which are presented as significantly less expensive than traditional comprehensive medical screenings. Overall, PREDILIFE stands out as an innovative healthcare company with a strong blend of scientific credibility, technological depth and scalable prevention-oriented solutions.